Vulvar Cancer

P1/2, N=50, Not yet recruiting, Centre Leon Berard

In peri-tumour specimens C-reactive protein immune expression was significantly higher than in lichen sclerosus specimens. No statistically significant differences were found between intratumour and lichen sclerosus specimens. No statistically significant difference between each type of specimens acquired in the group of patients diagnosed with lichen sclerosus and the specimens acquired in the group of patients diagnosed with vulvar cancer regarding Lysophosphatidic Acid immune expression was detected.

PAI-1 inhibitor TPX showed a strong inhibitory effect on VSCC cells, significantly reducing their viability, proliferation, migration and invasive capacity. This compound showed a strong ability to suppress important cell functions associated with cancer progression, making it a promising candidate for VSCC therapy to specifically inhibit growth and spread of VSCC.

P1/2, N=51, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed

P2, N=28, Not yet recruiting, GOG Foundation

p16(INK4a) expression predicts treatment response, locoregional disease control and survival in LAVC undergoing upfront CRT. These findings highlight the importance of integrating p16 expression into treatment protocols and future clinical trials.

P2, N=30, Recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Not yet recruiting --> Recruiting

The strongest expression in dVIN-associated VSCC highlights a possible link between aggressive tumor behavior and PRAME. dVIN-associated lesions may therefore represent promising candidates for PRAME-targeted therapy.

P2, N=798, Active, not recruiting, National Cancer Institute (NCI) | Trial primary completion date: May 2027 --> May 2026

P2, N=80, Recruiting, MacroGenics | N=60 --> 80 | Trial completion date: Aug 2027 --> Dec 2027 | Trial primary completion date: Feb 2027 --> Jul 2027

P=N/A, N=112, Active, not recruiting, Wake Forest University Health Sciences | Trial completion date: Mar 2027 --> Oct 2026 | Trial primary completion date: Aug 2026 --> Mar 2026

HLS shows neither the classic morphology of LS nor dVIN but can be p53 aberrant/mutant. Because of its CK17/D2-40 immunophenotype, it should be considered as atypical LS.